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Abstract
Background: Venous leg ulcers are common, chronic wounds that are painful and reduce quality of life.
Compression therapy is known to assist in the healing of venous leg ulceration. Supervised exercise training
that targets an improvement in calf muscle pump function might be a useful adjunctive therapy for enhancing ulcer
healing and other aspects of physical and mental health. However, the evidence of exercise for individuals with venous
ulcers is sparse. Here, we describe the protocol for a study that aims to assess the feasibility of undertaking a
randomised controlled trial of a supervised exercise programme in people who are receiving compression for
venous ulceration.
Methods/Design: This is a randomised, controlled, assessor-blinded, two-centre, feasibility trial with two
parallel groups. Eighty adults who are receiving lower-limb compression for a venous leg ulcer will be randomly
assigned to receive usual care (compression only) or usual care plus a 12-week supervised exercise programme.
Participants in the exercise group will be invited to undertake three, 60-minute sessions of supervised exercise each
week, and each session will involve a combination of treadmill walking, upright cycling and strength and flexibility
exercises for the lower limbs. Participants will be assessed before randomisation and 3, 6 and 12 months after
randomisation. Primary outcomes include rates of recruitment, retention and adherence. Secondary outcomes
include time to ulcer healing, proportion of participants healed, percentage and absolute change in ulcer size,
health-related quality of life (EQ-5D-5L and VEINES-QOL/Sym), lower-limb cutaneous microvascular function
(laser Doppler flowmetry coupled with iontophoresis) and physical fitness (30-second sit-to-stand test, chair sit
and reach test, 6-minute walk test and ankle range of motion). The costs associated with the exercise
programme and health-care utilisation will be calculated. We will also complete interviews with a sub-sample
of participants to explore their experiences of having a venous ulcer and the acceptability of the exercise
intervention and study procedures.
Discussion: Data from this study will be used to refine the supervised exercise programme, investigate the
acceptability of the intervention and study design and determine the most appropriate outcome measures,
thereby providing estimates of the factors needed to design an adequately powered trial across several
centres.
Trial registration: Current Controlled Trials, ISRCTN10205425 (May 2014) - http://www.controlled-trials.com/
ISRCTN10205425
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Background
Venous ulceration is the most common type of leg ulcer-
ation. The occurrence of venous leg ulcers increases
with age, and the annual UK prevalence in those over
65 years is estimated at 1.7 % [1]. Venous ulcers arise
from venous valve incompetence and calf muscle pump
insufficiency which leads to venous stasis and hyperten-
sion. This results in microcirculatory changes and local-
ised tissue ischaemia [2, 3]. The natural history of the
disease is of a continuous cycle of healing and break-
down over decades, and chronic venous leg ulcers are
associated with considerable morbidity and impaired
quality of life [4]. Treatment of this major health prob-
lem results in a considerable cost to the National Health
Service (NHS). The cost of treating one ulcer was esti-
mated to be between £1,493 and £1,795 per year on the
basis of 2010–2011 prices and in the context of a trial
conducted within the UK NHS [5].
A first-line treatment for venous ulcers is compression
therapy, the objective of which is to provide graded ex-
ternal compression to the leg and oppose the hydrostatic
forces of venous hypertension [6]. Cochrane reviews
have concluded that compression therapy is effective for
promoting ulcer healing [7] and reducing the risk of
ulcer recurrence [8]. O’Meara and colleagues [7] also
concluded that multi-component systems delivering high
compression (defined as 40 mm Hg of compression at
the ankle) were the most effective treatment for venous
ulcers. A recent trial demonstrated that two-layer com-
pression hosiery is equally effective as four-layer banda-
ging for the healing of venous ulcers [5].
Lifestyle factors, including nutrition, exercise and smok-
ing, are also mentioned in guidelines on the management
of venous ulceration and chronic venous insufficiency
(CVI) [9]; however, these factors receive relatively little
emphasis. Exercise training that targets an improvement
in calf muscle pump function might be a particularly use-
ful adjunct therapy for enhancing ulcer healing and other
aspects of physical and mental health. Exercise training is
routinely prescribed for other forms of cardiovascular dis-
ease such as peripheral arterial disease [10] and coronary
artery disease [11]. In patients with venous leg ulcers, su-
pervised calf muscle exercise has been shown to increase
calf muscle pump function and improve lower-limb
haemodynamics [12, 13], and supervised treadmill walking
exercise has been shown to improve lower-limb skin
microvascular function in individuals with mild CVI [14].
However, a recent systematic review concluded that fur-
ther research is required to determine whether exercise
training has a beneficial effect on ulcer healing and
health-related quality of life [15].
In light of this background evidence, we hypothesised
that a specially designed supervised exercise programme
delivered in conjunction with compression therapy would
be a more effective means of promoting venous ulcer
healing than compression therapy alone. Before embark-
ing on an adequately powered randomised trial to test
this hypothesis, we have planned a preliminary study
that will address several areas of uncertainty. For ex-
ample, leg pain and the perception that exercise might
be harmful or too difficult to perform have been iden-
tified as barriers to exercise in people with venous ul-
cers [16], and this raises questions about how easy it
will be to recruit and retain participants in a trial of a
supervised exercise programme. The specific aims of
the present feasibility study are the following:
1. Estimate the rates of recruitment and retention for a
future definitive trial of a 12-week supervised exercise
programme
2. Estimate the rates of attendance to and compliance
with the supervised exercise programme
3. Estimate the outcome completion rate (provision of
data) immediately after the intervention ends and at
12 months after randomisation to identify any
potential differences in completion between those
randomly assigned to exercise and those randomly
assigned to control
4. Identify a primary outcome and estimate the sample
size for a subsequent definitive trial
5. Refine a framework to facilitate conducting a
cost-effectiveness analysis of the intervention
6. Conduct post-intervention interviews with participants
to refine the design and delivery of the supervised
exercise programme.
Methods/Design
Study design
The FISCU (Feasibility of Implementing Supervised ex-
ercise training alongside Compression therapy in people
with venous Ulceration) study is a mixed methods feasi-
bility study involving an exploratory randomised con-
trolled trial with a nested qualitative component. Eighty
adults who are receiving lower-limb compression for a
new venous ulcer will be randomly assigned 1:1 to re-
ceive usual care (compression only) or usual care plus a
12-week supervised exercise programme. Participants
will be followed up until 12 months after randomisation.
The study is being run across two centres: Sheffield and
Lincoln, UK. The study is registered with the Inter-
national Standard Randomized Control Trial Number
Register (ISRCTN10205425) while the study protocol
conforms to the Spirit Checklist (Additional file 1).
This study started in May 2014 and is due to last until
May 2017. The trial is sponsored by the Sheffield Health
and Social Care NHS Foundation Trust, and ethical ap-
proval was granted by the NHS National Research Ethics
Service, Yorkshire and the Humber (Sheffield) Committee
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(14/YH/0091), which co-ordinates ethical permissions
across the following study and recruitment sites:
– Sheffield Hallam University
– Sheffield Health and Social Care NHS Foundation
Trust
– Sheffield Teaching Hospitals NHS Foundation Trust
– Sheffield Clinical Commissioning Group
– University of Lincoln
– Lincolnshire Community Health Services NHS
Trust.
Recruitment of participants
In both Sheffield and Lincoln, participants will be re-
cruited from community nursing and tissue viability
teams or services, family doctor practices, community
and outpatient leg ulcer clinics, and wound clinics. The
primary mode of identifying potentially eligible patients
will be through the weekly screening of primary care-
based electronic record systems by practice nurses, tis-
sue viability nurses, or specially trained administrators.
Poster advertisements will also be used.
Eligible individuals will be sent an invitation letter, a
brochure about the study, containing an invitation letter
(including the contact details of a research team mem-
ber), and a reply slip. For those recruited directly from
primary care, the invitation letters are sent by the pri-
mary care practice where the search was conducted. For
those recruited from existing databases, the invitation is
sent from the chief investigator. Individuals who are in-
terested in taking part are asked to return a reply slip
directly to the FISCU research team. Patients who satisfy
telephone pre-screening will be invited to the Centre for
Sport and Exercise Science at Sheffield Hallam Univer-
sity or the Human Performance Centre at the University
of Lincoln for their first formal study visit, during which
they will be habituated with the trial, provide written in-
formed consent (obtained by a research assistant or clin-
ician), be confirmed for eligibility by a clinician, and
complete baseline assessments.
Eligibility criteria
Patients are eligible for the trial if they:
– are at least 18 years of age
– have at least one venous leg ulcer of primarily
venous aetiology (determined by a clinician) with a
maximum diameter of at least 1 cm
– have an ankle brachial pressure index (ABPI) of at
least 0.8 (recorded within the previous 3 months)
– are able and willing to tolerate lower-limb
compression.
Patients are excluded from the trial if they:
– are unsuitable or unable to exercise (determined by
a clinician)
– are unable or unwilling to tolerate lower-limb
compression
– have insulin-controlled diabetes mellitus
– are pregnant
– have coexisting skin conditions, vasculitis, deep
venous occlusion or malignant/atypical ulceration
– require major surgery
– have a leg ulcer with a maximum diameter of less
than 1 cm
– have had an ulcer at the same site within the
previous 3 months
– are unable or do not wish to consent to
participation in the trial.
Baseline measurements
In visit 1, after written informed consent has been ob-
tained and eligibility confirmed (which will include a
medical examination), the following baseline measure-
ments will be recorded:
– demographic data, including age, sex, and
socioeconomic status
– clinical history, including incident or recurrent ulcer,
duration of ulcer disease, duration of current ulcer
(oldest ulcer and reference ulcer if different),
previous operations, comorbidities, current
medications, height, weight, ankle and calf
circumference
– ulcer size: measurement of ulcer size will involve
taking a leg ulcer tracing by using a fine-nibbed
indelible pen onto a conformable acetate film with a
pre-printed grid. When a participant has multiple
venous ulcers, all ulcers will be traced, and the
eligible ulcer with the largest surface area will be
deemed the reference ulcer for the trial. The reference
ulcer and any other ulcers will be drawn onto a leg
diagram. A digital image of the reference ulcer will
also be taken.
– ABPI: a Doppler-determined measurement of ABPI
will be performed according to the procedures of
Aboyans et al. [17] unless a reading of less than
3 months old has been obtained from clinical records.
– baseline exercise history
– health status: EQ-5D-5L [18]
– disease-specific quality of life and symptoms:
VEINES-QOL/Sym [19]
– lower-limb cutaneous microvascular function (see
Outcome Measures section for detailed description)
[14, 20]
– physical fitness, using three items from the Senior
Fitness Test (see Outcome Measures section for
detailed description) [21] and ankle range of motion
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assessed by using a bi-plane ankle goniometer
(maximum dorsiflexion through to maximum
plantarflexion).
Randomisation and masking
After completion of baseline assessments, participants
will be randomly assigned 1:1 to an intervention group
or a control group. The research assistant will request
(via email) a participant’s allocation from the trial statis-
tician (AG) who manages the randomisation schedule.
The statistician is not involved in the recruitment or
data-gathering processes and is based in a different loca-
tion to where the study visits are completed. Participants
will be stratified by ulcer size (maximum ulcer diameter
of either between 1 and 3 cm or greater than 3 cm in
any direction) with permuted blocks of variable size, be-
cause this criterion is a known predictor of ulcer healing
[22]. We could not mask participants or intervention su-
pervisors to the allocated treatment. Outcome assessors
will be blinded to group allocation.
Withdrawals
Participants will be considered to be withdrawn from
the trial if they request to leave the trial, if they are lost
to follow-up, or if they die before completing the 12-
month follow-up. Participants will be considered to be
withdrawn from the allocated treatment if they no lon-
ger receive the supervised exercise training if allocated
to the exercise group or if they no longer receive com-
pression therapy regardless of which group they are in.
Treating nurses will be asked to keep the participant
with their original compression therapy (i.e., bandaging
or stockings) unless there are objective clinical reasons
for changing. Withdrawals from the trial and from the
allocated treatment will be included in the analysis by
intention-to-treat.
Supervised exercise programme
A description of the supervised exercise programme is
provided separately (Additional file 2). Participants allo-
cated to the intervention group will be invited to attend
three sessions of supervised exercise each week for
12 weeks (total of 36 sessions) at one of the two study
exercise training facilities (Sheffield Hallam University
and University of Lincoln). Sessions will typically be deliv-
ered on Mondays, Wednesdays and Fridays to allow suffi-
cient recovery between sessions, although the weekly
training structure will be flexible to work around partici-
pants’ commitments. The 12-week programme duration
was chosen on the basis of a median ulcer healing time of
9 to 11 weeks for patients receiving compression therapy
[23]. Sessions will be performed in the late morning, after-
noon or early evening, given the higher occurrence of ad-
verse cardiovascular events during early-morning exercise
[24]. A maximum of 14 weeks will be allowed for the par-
ticipants to complete the 36 sessions in case sessions are
missed because of, for example, illness or holiday.
Each exercise session will last approximately 60 mi-
nutes and will comprise a combination of aerobic, resist-
ance and flexibility exercises. Each session will begin and
end with 5 minutes of low-intensity treadmill walking or
cycling for a warm-up and cool-down, respectively. The
aerobic component will last approximately 30 minutes,
and whether the exercise mode is treadmill walking, cyc-
ling, or a combination of both is determined by the
physical function and preference of participants. Tread-
mill hill-walking will be the preferred mode since it pro-
motes greater recruitment of the calf musculature than
cycling. The intensity will be moderate and this is due to
evidence that moderate-intensity exercise training im-
proves cardiorespiratory fitness, cardiovascular health,
venous vascular function and skin microvascular func-
tion [14, 25, 26] and the fact that it will likely be better
tolerated than high-intensity exercise. The intensity of
exercise will be guided by the use of Borg’s 6- to 20-point
exertion scale [27]; participants will exercise at an exertion
level of 12 to 14 (somewhat hard), which equates to the
ventilatory threshold [28]. The use of relative intensities
will ensure that the exercise programme has inherent pro-
gression as the participants become fitter. Perceived exer-
tion, heart rate (via telemetry) and exercise settings (e.g.,
treadmill speed and gradient) will be recorded at 5-minute
intervals during aerobic training to allow accurate quanti-
fication of the exercise stimulus and progression of the
programme over time.
Resistance and flexibility exercises will be performed
for approximately 20 minutes in order to improve calf
muscle pump function, leg (predominantly calf ) muscle
strength, and joint (predominantly ankle) mobility. Re-
sistance exercises will predominantly involve dynamic
body-weight exercises with or without the use of dumb-
bells and stability balls (e.g., calf raises and partial
squats). Exercise will be performed for two or three sets
of 10 to 15 repetitions to the point of moderate muscle
fatigue [29]. For flexibility, static stretches will be per-
formed for all of the major muscle groups of the legs,
for a total of 60 seconds per muscle group (comprising
3 × 20-second stretches), held at the point of mild dis-
comfort [29].
A trained exercise physiologist will supervise each ses-
sion, and there will be a maximum of four participants
per session to help ensure patient safety, successful de-
livery of the exercise session and collection of data.
Compression garments (stockings/bandages) will be
monitored during each exercise session: if affected by
exercise, participants will be referred to the tissue-
viability nursing team for re-application, and additional
visits will be noted for the health-economics analyses.
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An experienced clinical exercise physiologist (GT) will
be responsible for ensuring treatment fidelity of the ex-
ercise programme at both training sites.
After the completion of the intervention period, all ex-
ercise group participants will receive a personalised leaf-
let including an exercise programme that they could
manage on their own. Adherence to those instructions
will be monitored at follow-up visits.
Usual care
Participants from both groups will receive standard com-
pression therapy directed by experienced tissue-viability
nurses, according to their individual circumstances and
following standard local practice (e.g., multi-layered com-
pression bandaging or two-layer compression stockings as
well as standard advice to elevate the affected leg). Pa-
tients will be reviewed in clinics as often as is deemed
clinically necessary.
Study outcomes
All staff of the respective trial sites have been trained on
the study protocol, informed consent and assessment
data collection procedures. Study-specific standard oper-
ating procedures have also been developed to help ensure
consistent data collection procedures between different
outcome assessors and sites. Outcome assessors will be
blinded to group allocation.
Follow-up visits for assessment of outcome measures
will be completed 3 months (i.e., soon after the end of the
supervised exercise programme) and 12 months after ran-
domisation. A postal questionnaire follow-up will also be
conducted 6 months after randomisation.
Feasibility outcomes
The main focus of this study is acceptability and feasibil-
ity of procedures for recruitment, allocation, measure-
ment and retention and for the intervention procedures.
Recruitment rates will be measured as rate of invited
participants who are eligible and consenting and will be
reported in a CONSORT (Consolidated Standards of
Reporting Trials) participant flowchart. Acceptability of
allocation procedures will be assessed by examining rea-
sons for dropout in discontinuing participants and com-
paring attrition rates between the two study groups.
Suitability of measurement procedures will be evaluated
on the basis of completion rates and reasons for missing
data. Attrition rates will be established as discontinu-
ation of intervention and loss to follow-up measurement
for all conditions. The acceptability of the exercise pro-
grammes will be assessed by using session attendance
and compliance data and participant feedback via one-
to-one semi-structured interviews conducted with a
sub-group of participants after the 3-month follow-up
visit. The safety of exercise training will also be
assessed by exploring reasons for dropout from the ex-
ercise programme and the number and type of adverse
events that occur in each group.
Secondary outcomes
Time to reference ulcer healed
Healing will be defined as complete epithelialisation in
the absence of scab/eschar. The treating nurse will in-
form a study investigator when the reference ulcer and
last ulcer (if applicable) have healed. A digital photo-
graph of the reference/last ulcer site will be taken for
validation purposes at healing and 7 days after healing.
These images will be assessed ‘blind’ for confirmation
of healing.
Proportion of patients healed
The proportion of patients healed will be assessed 3, 6
and 12 months after randomisation. This will allow dir-
ect comparison with other trials.
Percentage and absolute change in ulcer size
Percentage and absolute change in ulcer size will be
measured 3 and 12 months after randomisation. The
data collected will allow the determination of reduction
in ulcer area in patients who do not achieve complete
ulcer healing. Measurement of ulcer size will involve tra-
cing on acetate films, as described above.
Proportion of time patients are ulcer-free
Reduction in recurrence would help reduce the preva-
lence of this condition and thus cost. Crude recurrence
rates are potentially biased by any difference in healing
rates associated with the two groups (exercise or con-
trol) since if one group has more rapid healing, then
people in that group are at risk of earlier recurrence. To
account for this, we will use the proportion of time that
patients are ulcer-free as the clinically important meas-
ure since it is a function of both healing and recurrence
and it is important for patients. Recurrence data will be
collected 3, 6 and 12 months after randomisation.
Health-related quality of life
Health-related quality of life will be assessed 3, 6 and
12 months after randomisation by using the EQ-5D-5L
and VEINES-QOL/Sym. The EQ-5D is a generic meas-
ure of health status, in which health is characterized on
five dimensions (mobility, self care, ability to undertake
usual activities, pain and anxiety/depression) [18]. Partic-
ipants will be asked to describe their level of health on
each dimension by using one of five levels: no problems,
slight problems, moderate problems, severe problems or
extreme problems. The EQ-5D has been validated in the
UK and was used in the Venous leg Ulcer Study III
(VenUS III) and VenUS IV trials [5, 30]. The VEINES-
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QOL/Sym is a disease-specific quality-of-life instrument
for use in venous diseases of the leg [19].
Lower-limb cutaneous microvascular function
Laser Doppler fluximetry and iontophoresis will be used
to assess cutaneous microvascular function [31] in the gai-
ter area of the affected leg. We will assess areas of skin
that are in close proximity to the ulcer but at least 3 cm
away from the edge of the ulcer. Assessments will be per-
formed in a temperature-controlled room (22–24 °C) with
the participants in a supine position and the leg elevated
at 30°. Compression garments will be removed only if pa-
tient care is not compromised (e.g., removable compres-
sion stockings are worn). Heart rate (Sports Tester; Polar,
Kempele, Finland) and blood pressure (left arm; Dinamap
Dash 2500; GE Healthcare, Wauwatosa, WI, USA) will be
monitored at 5-minute intervals throughout the protocol.
The two drug delivery electrodes (PF383; Perimed AB,
Jarfalla, Sweden) will be positioned over healthy-looking
skin, approximately 4 cm apart; one will contain 100 μl of
1 % acetylcholine chloride (ACh) (Miochol-E; Novartis,
Stein, Switzerland) and the other 80 μl of 1 % sodium
nitroprusside (SNP) (Nitroprussiat; Rottapharm, Monza,
Italy), and de-ionised water will be used as the solvent.
A battery-powered iontophoresis controller (PeriIont
PF382b; Perimed AB) will be used to provide the charge
needed for the simultaneous delivery of ACh and SNP.
A 4-minute stable recording of baseline flux will be
followed by administration of the two agents in accord-
ance with the following protocol: 0.2 mA for 10 seconds
(i.e., 2 mC), 0.2 mA for 15 seconds (i.e., 3 mC), 0.2 mA
for 20 seconds (i.e., 4 mC), and 0.3 mA for 20 seconds (i.e.,
6 mC), with 4-minute intervals between each dose. To
obtain an index of skin blood flow, cutaneous red cell flux
will be measured by placing an iontophoresis laser-Doppler
probe (PF481-1; Perimed AB) connected to a laser Doppler
fluxmeter (PF5001; Perimed AB). Responses to ACh and
SNP will be used as indicators of the changes occurring in
the endothelial-dependent and -independent vasodilatory
function, respectively. The process will be repeated in the
gaiter area of the non-affected leg following a 10-minute
resting period.
Physical fitness – Senior Fitness Test
The Senior Fitness Test is a widely used test battery for
evaluating the effects of exercise interventions in older
adults and consists of six sub-tests which measure the
physical abilities needed to perform activities of daily liv-
ing [21]. However, three of the sub-tests—for upper-
body flexibility, upper-body strength, and agility—will
not be used, as these aspects of physical fitness are not
targeted within the exercise intervention. Therefore, the
tests used in this trial will be (i) 30-second chair-stand
test for lower-body muscular strength and endurance
(the number of times in 30 seconds a participant can
stand fully from a seated position without using their
arms), (ii) chair sit and reach test for lower body flexibil-
ity (from a sitting position at front of chair, with leg ex-
tended and hands reaching toward toes, the number of
centimetres (+ or −) between extended fingers and tip of
toe), and (iii) the 6-minute walk test for aerobic fitness
(the maximum distance a participant can walk in 6 mi-
nutes). All tests will be measured once, except the sit
and reach tests, which will consist of a practice, then
two trials. The Senior Fitness Test has acceptable test-
retest reliability (R = 0.81–0.98) and construct validity
against a range of indicators, such as age and exercise
status, and criterion validity (r = 0.71–0.82) [32].
Adherence to background clinical therapies
All participants will be asked to complete specially de-
veloped, self-reported diaries for their adherence to leg
elevation instructions, usage of compression therapy and
contact time with the tissue-viability nursing team to as-
sist the full-study and health-economic analysis. This
procedure will be supported by weekly phone calls from
a research team-member at all stages.
Health economics
The broader aim is to undertake a comprehensive cost-
utility analysis with both NHS and societal perspectives.
However, in this feasibility study, the primary objective
is to account for as well as make fair assessment and
valuation of costs (direct and indirect costs) and benefits
(quality-adjusted life-year (QALY) gains) as a result of
the 12-week exercise intervention. The major cost
drivers will be patient’s use of NHS and private health
services, the patient’s time and their travel costs and
intervention delivery costs.
Cost of intervention This will include staff time, in-
cluding exercise instructor related to intervention deliv-
ery, resources and equipment used and room costs as
well as any incentive given to patients to adhere to the
exercise session.
Costs to patients in the intervention group This will
be based on the distance to the exercise training facility
and travel costs, time taken off from work to attend the
exercise session and any additional equipment/aids/
shoes and bandage/dressing purchased to undertake ex-
ercise sessions.
Difference in resource use between intervention and
control groups The resource use questionnaire will be
completed by intervention and control groups at 3-, 6-
and 12-month intervals to elicit information on utilisation
of NHS and private health-care services related to leg
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ulcer treatment. It collects information on the number of
visits, travel time and cost, and cost to the patient for the
following uses: General practitioner; Doctor at leg ulcer
clinic; NHS Hospital consultant/specialist; Doctor/nurse
at accident and emergency; NHS Physiotherapist; Private
Physiotherapist; Private doctor/consultant; Private chiro-
practor; Psychologist/counsellor; and Any other. Similarly,
the number of times and the costs to the patient for
undertaking diagnostic tests (e.g., x-rays, computed
tomography scan, magnetic resonance imaging scan,
blood test and any other tests) and for medications
(e.g., pain killers, sleeping pills and antibiotics) and
other aids (e.g., compression hosiery or bandages)
related to leg ulcer will be collected. Furthermore,
number of days of hospitalisation related to leg ulcer
and data on costs for any equipment purchased for
speedy recovery from leg ulcer will be collected.
Difference in time taken off from work between
intervention and control groups The patient’s work sta-
tus, employment type (full-time, part-time, self-employed,
unpaid work, unemployed and inactive) and the number
of days off from work because of leg ulcer will be
accounted for in presenting the societal perspective on
costs and benefits of the intervention. The changes in the
employment status because of leg ulcer will be recorded
during the intervention and follow-up period.
Differences in quality of life between intervention
and control groups The new EQ-5D-5L questionnaire
will be used to measure quality of life at baseline and at
3-, 6- and 12-month intervals. Using the standardised
general population-based tariff, the scores will be con-
verted into QALYs and then compared between inter-
vention and control groups.
Incremental cost-effectiveness ratio To measure the
net effect of intervention, the incremental cost-effectiveness
ratio will be derived from relating differences in costs to
benefits between intervention and control groups during a
12-month period. We will use standard published sources
for unit costs where available and supplement this with
local sources if required. We will use the same methods of
analysis as in a definitive trial, including imputation
methods for missing data, analysis of uncertainty and
non-normal distributions: that is, standard statistical
analysis of costs will be performed to test for statis-
tical significance of results, while bootstrapping would
be performed to estimate the confidence interval (CI)
of average interventional costs.
Qualitative component
The aim of the qualitative component is to explore partici-
pants’ experiences of having a venous ulcer and the
acceptability of the exercise intervention and study proce-
dures. A sub-sample of 16 participants will be recruited by
using purposive sampling (mixture of genders, younger and
older participants from intervention and control groups).
Semi-structured interviews of up to 1 hour will be con-
ducted with participants either face-to-face or via telephone
(participants’ preference) after the 3-month follow-up visit.
The following topics will be explored:
– participants experiences’ of leg ulceration
– experiences of treatment and advice given
– participants’ preference for trial allocation
– participant acceptability of the exercise intervention
and study procedures.
Transcripts will be analysed thematically by using
framework analysis as this approach provides a system-
atic process to analyse qualitative data. The in-depth
interview offers an opportunity to investigate in detail
participant’s personal perspectives of their leg ulcer ex-
periences set within their personal frame of reference.
The interview method also means that there will be time
to explore participant’s motivations, attitudes, interven-
tion impact and experiences in greater detail than that
afforded by a focus group setting [33]. Framework ana-
lysis [34] offers an approach that is somewhat inductive;
that is, it is based in the original interview transcripts
but framed within the “constraints” of an a priori frame-
work. An audio recording of the interviews will be made
and then transcribed verbatim, and the five stages of
framework analysis (familiarisation, identifying a the-
matic framework, indexing, charting and mapping) will
be followed.
Statistical analysis
The sample size for a feasibility study should be ad-
equate to estimate critical metrics, needed to assess the
feasibility of conducting the definitive study, with suffi-
cient precision. Herein, the critical metrics are the con-
sent rate (i.e., the proportion of eligible patients who
consent to participate and be randomly assigned), ulcer-
healing rates and compliance with treatment, and attri-
tion. Forty patients in each group will provide a suffi-
ciently precise (within 15 percentage points for a 90 %
CI) estimate of the proportion willing to be randomly
assigned, assuming 35–40 % intention to be randomly
assigned. A sample size for an adequately powered ran-
domised controlled trial will be determined from the re-
sults of this trial.
Descriptive statistics will be used to characterise the
groups at baseline and to present the feasibility out-
comes described above. Although determining differ-
ences in clinical outcomes between the two arms is not
the primary purpose of this trial, comparisons will be
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undertaken to investigate the feasibility of studying these
outcomes and to calculate estimates for the likely ef-
fect sizes and 95 % CIs. Analyses will be conducted
in SPSS by using the principles of intention-to-treat.
Significance tests will be two-sided at the 5 % level.
Healing rates will be compared by using the Kaplan-
Meier method. Hazard ratios and 95 % CIs will be
presented for ulcer healing time by using Cox regres-
sion analysis models. For other outcomes, the inter-
vention and control groups will be compared by
using linear or logistic regression (depending on the
type of outcome) adjusting for ulcer size and any
other important baseline covariate. Relevant assump-
tions will be checked for all models. For the potential
primary outcomes for a definitive trial, the likely ef-
fect of the exercise intervention will be estimated via
standard intervention minus control comparisons, ac-
counting for the type of variable and its distributional
properties. We will examine whether the CIs include
potentially clinically important effects in outcomes be-
tween groups. As this is a feasibility study, these
comparisons are exploratory and are intended to in-
form the subsequent, definitive trial.
Criteria for success
This feasibility trial will be deemed successful and lead
to the development of a proposal for an adequately pow-
ered randomised controlled trial if:
(i) An appropriate primary outcome variable is defined
(ii)At least 67 % of randomly assigned patients in the
exercise group are compliant with the intervention
(defined as at least 75 % of the scheduled sessions
are completed as planned)
(iii)Loss to follow-up at 12 months is less than 20 %
(iv)Patient preferences are not so strong that they
result in the conclusion that a randomised
controlled trial is not a feasible design.
The criteria for success will provide the basis for inter-
preting the results of this study and determine whether
it is appropriate to proceed to a full trial and (if appro-
priate) what modifications need to occur for a full trial
to be feasible.
Project management
The management of this study will be the responsibility
of the research management group, consisting of the
chief investigator (MK), all co-applicants (including GT,
HC, JM and AG) and all research staff. Operational
management will be the responsibility of the research
team consisting of the chief investigator, the principal
investigator in Lincoln (GM) and research staff, meet-
ing once a week to ensure adherence to planned
timescale, adherence to the intervention and detailed
plans for data management and analysis. A trial steering
committee consisting of independent clinical (Ian Chetter
and Brenda King) and academic members (Jude Watson
and Catherine Hewitt) and the chief investigator (MK) will
also meet at least twice a year. This committee is respon-
sible for the overall management and oversight of the trial.
Because of the low-risk nature of this trial (both treat-
ments being assessed were already being used routinely in
clinical practice), we did not judge it necessary to have a
separate Data Monitoring and Ethics Committee to over-
see the trial. This study was co-adopted to the Primary
Care and Dermatology specialities of the UK Clinical
Research Network Portfolio (UKCRN ID 16665), which
provides research infrastructure resources, including
Research Nurse support for recruitment.
Discussion
Venous leg ulcers may take many months to heal (and
some do not) and during this time they result in signifi-
cant suffering for patients and represent substantial
cost to the NHS. At present, compression is the main
treatment for venous ulceration and few additional
therapies exist to improve healing. The FISCU study
will provide preliminary evidence about the effective-
ness of supervised exercise training as an adjunct ther-
apy for enhancing ulcer healing, physical fitness and
health-related quality of life in people with venous ul-
cers. The findings will inform a future definitive multi-
centre randomised controlled trial with a larger sample
size. Strengths of the current preliminary study include
follow-up through 12 months after randomisation, use
of a strategy to assess the fidelity of the intervention,
and inclusion of relevant objective and patient-reported
outcome measures. A limitation of this study is that
there are only two recruiting sites and this may limit
the generalisability of the findings. The external validity
of university-based exercise training may also be ques-
tionable given that supervised exercise training is un-
likely to be delivered in this setting if it were to become
an established part of the management of venous ulcer-
ation. Benefits of using a university setting in the
current study include the availability of dedicated exer-
cise facilities for research purposes and free parking.
These issues of generalisability will be addressed in the
future main study by having more (probably more than
10) trial sites and using existing NHS resources for de-
livering the intervention (e.g., hospital or community-
based cardiac rehabilitation programmes).
Trial status
Recruitment started in July 2014 and is ongoing.
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